PomDoctor Receives Nasdaq Deficiency Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy POM?
PomDoctor announced that it has received a written notification from the staff of Nasdaq dated January 29, indicating that for the last 33 consecutive business days, the closing bid price of the company's American depositary shares was below the minimum bid price of $1.00 per share requirement set forth in Nasdaq Listing Rule 5450. The Deficiency Letter has no current effect on the listing or trading of the company's ADSs on Nasdaq. Pursuant to Nasdaq Listing Rule 5810, the company is provided with a compliance period of 180 calendar days, or until July 28, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the compliance period, the closing bid price of the company's ADSs is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide the company a written confirmation of compliance and the matter will be closed. In the event the company does not regain compliance by July 28, subject to the determination by the staff of Nasdaq, the company may be eligible for additional time. The deficiency letter will have no effect on the company's business operations, and the company will take all reasonable measures to regain compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy POM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Pomdoctor Securities Litigation Announced
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Pomdoctor Limited, specifically urging investors who purchased securities between October 9, 2025, and December 11, 2025, to apply for lead plaintiff status in a federal securities class action by the April 13, 2026 deadline.
- Stock Price Plunge: Pomdoctor's stock price fell from approximately $0.50 on December 10, 2025, to about $0.38 the following day, representing a decline of roughly $0.12 or 24% in a single trading session, reflecting widespread investor concerns regarding the company's financial performance and valuation.
- False Promotion Allegations: The complaint alleges that Pomdoctor and its executives violated federal securities laws by making false and misleading statements and failing to disclose fraudulent stock promotion schemes involving social media misinformation, leading to investor misconceptions about the company's prospects.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Pomdoctor's conduct, including whistleblowers and former employees, to contact the firm directly to provide information for potential legal actions, ensuring the protection of investor rights.
See More
Pomdoctor Investors Encouraged to Seek Legal Options
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Pomdoctor, particularly for investors who purchased securities between October 9, 2025, and December 11, 2025, aiming to protect investors' legal rights.
- Claim Deadline Reminder: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action is April 13, 2026, making this time frame critical for asserting their claims.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact numbers to facilitate consultations, demonstrating the firm's commitment to client support.
- Potential Impact Assessment: This investigation could negatively affect Pomdoctor's stock price and market confidence, prompting investors to stay informed about their legal options to take action if necessary.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that during the class period, PomDoctor was involved in a fraudulent stock promotion scheme that misled investors through social media misinformation and insider trading, which inflated stock prices and misrepresented the company's operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, highlighting its strong track record in this legal domain.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in class actions to ensure effective representation in the litigation process.
See More
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, or risk losing the opportunity to represent other investors.
- Fee Arrangement: Investors joining the PomDoctor class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme during the class period, with insiders using offshore accounts to dump shares, misleading investors and impacting the company's stock price performance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its expertise and success rate, which investors should consider when selecting legal counsel.
See More
PomDoctor Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against PomDoctor, aiming to recover damages for investors who purchased the company's securities between October 9 and December 11, 2025, highlighting serious investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that PomDoctor failed to disclose significant adverse facts regarding its business, operations, and securities trading activities during the class period, leading to investor misunderstandings that could impact stock prices.
- Insider Trading Suspicions: The lawsuit further claims that insiders used offshore or nominee accounts to facilitate coordinated share dumping, suggesting improper profit-taking during price manipulation activities, which increases the risk of investor losses.
- Investor Recourse Opportunity: Affected investors have until April 6, 2026, to request lead plaintiff status, with Bronstein, Gewirtz & Grossman, LLC offering risk-free representation, emphasizing their expertise and successful track record in securities fraud class actions.
See More
Investigation into Pomdoctor Securities Litigation Announced
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Pomdoctor Limited due to possible false statements made during securities transactions from October 9, 2025, to December 11, 2025, with a deadline for lead plaintiff applications set for April 13, 2026.
- Stock Price Volatility: Pomdoctor's stock price plummeted from approximately $0.50 to $0.38 between December 10 and 11, 2025, representing a 24% decline in a single trading session, reflecting investor concerns regarding the company's financial performance and eroding market confidence.
- False Promotion Allegations: The lawsuit alleges that Pomdoctor and its executives violated federal securities laws by failing to disclose involvement in fraudulent stock promotions and insider trading, misleading investors and negatively impacting the company's reputation and market value.
- Investor Rights Protection: Faruq & Faruq encourages affected investors to contact the firm to provide information supporting the litigation, ensuring that investors can secure their rightful claims in any potential recovery.
See More
Investigation into Pomdoctor Securities Litigation Announced
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Pomdoctor Limited, specifically urging investors who purchased securities between October 9, 2025, and December 11, 2025, to apply for lead plaintiff status in a federal securities class action by the April 13, 2026 deadline.
- Stock Price Plunge: Pomdoctor's stock price fell from approximately $0.50 on December 10, 2025, to about $0.38 the following day, representing a decline of roughly $0.12 or 24% in a single trading session, reflecting widespread investor concerns regarding the company's financial performance and valuation.
- False Promotion Allegations: The complaint alleges that Pomdoctor and its executives violated federal securities laws by making false and misleading statements and failing to disclose fraudulent stock promotion schemes involving social media misinformation, leading to investor misconceptions about the company's prospects.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Pomdoctor's conduct, including whistleblowers and former employees, to contact the firm directly to provide information for potential legal actions, ensuring the protection of investor rights.
See More
Pomdoctor Investors Encouraged to Seek Legal Options
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Pomdoctor, particularly for investors who purchased securities between October 9, 2025, and December 11, 2025, aiming to protect investors' legal rights.
- Claim Deadline Reminder: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action is April 13, 2026, making this time frame critical for asserting their claims.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact numbers to facilitate consultations, demonstrating the firm's commitment to client support.
- Potential Impact Assessment: This investigation could negatively affect Pomdoctor's stock price and market confidence, prompting investors to stay informed about their legal options to take action if necessary.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that during the class period, PomDoctor was involved in a fraudulent stock promotion scheme that misled investors through social media misinformation and insider trading, which inflated stock prices and misrepresented the company's operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, highlighting its strong track record in this legal domain.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in class actions to ensure effective representation in the litigation process.
See More
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, or risk losing the opportunity to represent other investors.
- Fee Arrangement: Investors joining the PomDoctor class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme during the class period, with insiders using offshore accounts to dump shares, misleading investors and impacting the company's stock price performance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its expertise and success rate, which investors should consider when selecting legal counsel.
See More
PomDoctor Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against PomDoctor, aiming to recover damages for investors who purchased the company's securities between October 9 and December 11, 2025, highlighting serious investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that PomDoctor failed to disclose significant adverse facts regarding its business, operations, and securities trading activities during the class period, leading to investor misunderstandings that could impact stock prices.
- Insider Trading Suspicions: The lawsuit further claims that insiders used offshore or nominee accounts to facilitate coordinated share dumping, suggesting improper profit-taking during price manipulation activities, which increases the risk of investor losses.
- Investor Recourse Opportunity: Affected investors have until April 6, 2026, to request lead plaintiff status, with Bronstein, Gewirtz & Grossman, LLC offering risk-free representation, emphasizing their expertise and successful track record in securities fraud class actions.
See More
Investigation into Pomdoctor Securities Litigation Announced
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Pomdoctor Limited due to possible false statements made during securities transactions from October 9, 2025, to December 11, 2025, with a deadline for lead plaintiff applications set for April 13, 2026.
- Stock Price Volatility: Pomdoctor's stock price plummeted from approximately $0.50 to $0.38 between December 10 and 11, 2025, representing a 24% decline in a single trading session, reflecting investor concerns regarding the company's financial performance and eroding market confidence.
- False Promotion Allegations: The lawsuit alleges that Pomdoctor and its executives violated federal securities laws by failing to disclose involvement in fraudulent stock promotions and insider trading, misleading investors and negatively impacting the company's reputation and market value.
- Investor Rights Protection: Faruq & Faruq encourages affected investors to contact the firm to provide information supporting the litigation, ensuring that investors can secure their rightful claims in any potential recovery.
See More
